Nova studija od Francija. Vakcinata go namaluva rizikot od tesko zaboluvanje za 90%:
https://www.epi-phare.fr/rapports-detudes-et-publications/impact-vaccination-covid-octobre-2021/
Translate FR->EN:
To assess the effectiveness of vaccination in preventing severe forms of Covid-19, EPI-PHARE carried out two real-life studies in parallel using data from the SNDS (National Health Data System), one in 15, 4 million people aged 50 to 74 (7.7 million vaccinated compared to 7.7 million unvaccinated) the other in 7.2 million people aged 75 and over (3.6 million vaccinated compared to 3 , 6 million unvaccinated). Both cohorts were followed until July 20, 2021.
Among those vaccinated aged 50 to 74, 53.6% (n = 4,158,306) had received Pfizer vaccine, 7.1% (n = 553,676) Moderna, and 39.2% (n = 3,042,930 ) AstraZeneca. Among those aged 75 and over, 85.3% (n = 3,109,133) had received Pfizer, 8.7% (n = 315,455) Moderna, and 6.1% (n = 221,156) AstraZeneca.
The results of these two studies are very consistent. They highlight the significant effectiveness of the three vaccines Pfizer, Moderna and AstraZeneca, against severe forms of Covid-19 (hospitalization for Covid-19 and death during hospitalization for Covid-19), with a reduction in risk hospitalization from the 14th day after the injection of the second dose greater than 90% in the two cohorts and for each vaccine. This reduction is of the same order of magnitude for the risk of death during hospitalization for Covid-19.
The effectiveness of vaccination on severe forms of Covid-19 did not seem to decrease over the available follow-up period, which went up to 5 months. In fact, in the cohort aged 75 and over, it was 94% at 5 months of follow-up for the Pfizer vaccine. It was 97% in the 50 to 74-year-old cohort at 4 months of follow-up. For the Moderna and AstraZeneca vaccines, the follow-up was too short to be able to study their effect at 4 or 5 months.
In order to examine the impact of the Delta variant, the reduction in the risk of hospitalization for Covid-19 was estimated specifically during the period of the start of circulation of the Delta variant in France, i.e. between June 20 and 20. July 2021. Over this period, the efficacy was 84% in the cohort aged 75 and over and 92% in the cohort aged 50 to 74. This approach, based on a short period, makes it possible to provide the first elements on the effect of the Delta variant on risk reduction.
In conclusion, all Covid-19 vaccines are highly effective and have a major effect on reducing the risk of severe forms of Covid-19 in people aged 50 and over in France in real life. Continued monitoring by EPI-PHARE will make it possible to measure the evolution of efficacy over a longer period and to better characterize the effects of the Delta variant.
www.nytimes.com
